Dermatology used to be thought of as a niche area. But our deeper understanding of what causes many skin diseases, has led to an explosion of interest. In our latest episode of #OptimumTV, Thibaud Portal and Brian Kim of Alys Pharmaceuticals explore what advances the company is making in the sector.
Old names for diseases can date – either because of our growing scientific understanding of what’s really going on, or because they can end up ‘victim blaming’ patients. But renaming them has its own problems – such as lack of recognition. Read #Optimum’s latest #HotTopic on the conundrum here ⬇️
📺The last 18 months have seen an explosion of interest in Chinese biotechs, #OptimumTV spoke to Lan Zhang, CEO of Crimson Gateway, whose deep local knowledge provides a helping hand for those looking to go “shopping” in China, as well as incubating early-stage biotechs itself.
It has been another dynamic week for Optimum’s clients with SpliceBio’s successful $135m Series B financing, AMSilk venturing into consumer care, Alys Pharmaceuticals’ CTA submission and the first of Sofinnova Partners’ portfolio companies accessing revolutionary #AI technology. Subscribe today ⬇️
📺Rescuing biotech’s fallen angels? In the latest episode of #OptimumTV, Nick Bastin sat down with #Alis Biosciences Founder and Board Member Nicholas Johnston to find out more about the firm’s innovative approach to returning this trapped capital to investors and resuscitating viable science.
Science is making amazing advances as delegates at ASCO 2025 recently witnessed. But there is also a great deal of scepticism about evidence-based treatments in the world at large – a problem getting worse due to misinformation on social media. Read #Optimum’s latest #HotTopic here ⬇️
Will we see you there? ON Helix is a great event which addresses key bio-innovation trends, generating discussions around the progress and future of the #LifeScience industry.
Optimum is a proud supporter of One Nucleus events, reach out if you would like to connect!
Its been a busy week in the industry from Amber Implants announcing the results of its 1yr follow-up data for VCFix to appointments with iOnctura bolstering its leadership team, and Asgard Therapeutics and Commit Biologics strengthening their advisory boards #OptimumNewsletter ⬇️
📺What options are there for life science companies to raise funds while there’s little appetite for IPOs? Marten Steen, Managing Partner at leading VC HealthCap, considers the possibilities in the latest #OptimumTV – although he predicts the situation will improve over the next 12 to 18 months.
It has been another great week for Optimum clients with Poolbeg being granted US FDA Orphan Drug Designation and Nucleome and STORM’s fantastic appointments. Subscribe to our weekly round-up to never miss an edition!
#OptimumNewsletter #HealthcareCommunications
#Biotech isn’t having the easiest time right now. But hard times, just like good times, don’t last forever, a subject our latest Hot Topic delves into. Read it here 👇
www.optimumcomms.com/hot-topic-bi...
From Poolbeg Pharma’s successful £4.865 million fundraising, to the deepening of Novo Nordisk Foundation’s partnership with WHO, it has been a week that has shown resilience despite turbulent market conditions. Subscribe to our newsletter to ensure you never miss an edition ⬇️
#OptimumNewsletter
Obesity drugs have largely been considered as nothing but a boon for pharma so far. But if they prove effective at cutting the risk of a range of serious diseases including cardiovascular and cancer, might they take a chunk out of other drugs’ revenues and profits? Read our latest hot topic ⬇️
📺As a biotech CEO, how do you raise funds when the market doesn’t seem interested? Watch former Ablynx CEO Edwin Moses talk to Optimum TV about the attributes needed to succeed – and why he’s still actively involved in the industry as a non-executive chair of several life science companies.
Summer is fast approaching and it is now less than five months until Optimum's 17th Annual Healthcare Conference! This prestigious invitation only event brings together investors and executives from across the life sciences sector, register your interest today: www.optimumcomms.com/irconference...
From Alchemab’s landmark $415m licensing agreement with Eli Lilly & Co to clinical milestones from iOnctura and Vesper Bio, Optimum’s clients have had a busy week! Never miss industry news and subscribe today ⬇️
#OptimumsNewsletter #HealthcareCommunications
The 1 week countdown to #BioEquityEurope is on!
Celebrating 25 years of this prestigious event, Optimum is proud to be sponsoring the networking breakfast.
Please reach out if you would like to connect with our CEO, Mary Clark and Associate Director, Zoe Bolt at the conference.
📺Most people have heard of Huntington’s disease - but not all really know what it is. To mark Huntington’s Disease Awareness Month, David Reynolds, CEO of LoQus23 Therapeutics, talked to #OptimumTV about its genetic underpinning, how it develops over time, symptoms, and modern treatment approaches.
Things are heating up in the life sciences industry with the exciting launch of blood cancer focused Cycuria Therapeutics, Novo Nordisk Foundation’s expansion of its Challenge Programme outside of Denmark for the first time, and Optimum clients featuring on The Medicine Maker Power List 2025! ⬇️
What does the price of eggs have to do with pandemics? On the face of it, not a lot. But in our new Hot Topic we discuss how a rampant bird flu outbreak in the US is impacting egg prices there – and, much more worryingly, getting virologists concerned about a fresh pandemic. Read it here ⬇️
It’s been an exciting week from the appointment of Renée Aguiar-Lucander as CEO of Hansa Biopharma, to the launch of Alis Biosciences - a fund aiming to free $30bn of trapped biotech capital, to a new edition of #OptimumTV’s Dealmakers series. Read the latest industry news below ⬇️
📺 In the latest episode of #OptimumTV’s Dealmakers series, watch Jonathan Tobin of Brandon Capital talk about Trump, the threat of #tariffs, and why things are likely to have settled down by this time next year. Watch the full episode below!
#HealthcareCommunications
Vaccine scepticism has grown in recent years and consequently the immediate outlook for research and development is somewhat clouded. On the eve of #WorldImmunizationWeek, our Hot Topic looks at their huge contribution to global health and the great strides being made in vaccine technology today ⬇️
The last fortnight has certainly been a rollercoaster… Read this week’s Hot Topic on the possible impacts of #TrumpTarrifs ⬇️
#HealthcareCommunications #AI #OptimumsHotTopic
www.optimumcomms.com/will-trump-h...
It is less than a month to go until the Optimum Team is in Bruges for the 25th anniversary edition of #BioEquityEurope!
Optimum is proud to be sponsoring the networking breakfast at this prestigious event.
Please reach out if you would like to connect with us there!
#HealthcareCommunications
From up-and-coming life science leaders to a clinical trial approval, keep up to date with the latest in the life sciences industry in Optimum’s weekly round-up! Make sure to never miss an edition and subscribe today ⬇️
#HealthcareCommunications #LifeSciences
When Sir Demis Hassabis’s London-based AI drug discovery outfit Isomorphic Labs announced last week it had raised $600m, the news certainly made headlines. While there are specific reasons his firm received such huge backing, this looks like a positive sign for biotech as a whole. Read more below ⬇️
📅 Save the date!
6 months today until Optimum's 17th Annual Healthcare Investor Conference returns to The King's Fund, London.
Register your interest here: www.optimumcomms.com/irconference...
#OptimumConference2025
It is 3 weeks until LSX's World Congress Europe, and the Optimum Team is looking forward to connecting with you all in London once again! As a proud supporter of the event, we are pleased to offer a 15% F&F discount to our wonderful network, please reach out if you would like to use this code.
Were you there? Read Optimum’s top take-aways from the 21st Anglonordic Life Science Conference. Attended by well over 300 delegates - it’s fair to say, it was a resounding success! www.optimumcomms.com/an-overview-...
Save the date for 2026 - Thursday, 23rd April!!
#lifesciences #Anglonordic
